AgingResearch.News
AHA Scientific Sessions 2025 Abstract

37,500 man-years of clinical expertise validate the cardio-metabolic benefits of empagliflozin-linagliptin in type 2 diabetes: findings from the amplified consensus

By Tiny Nair, Sushil Kumar Gupta, Ameya S Joshi, Show 8 more authorsPrakash Hazra
Interventions
Paper

The paper

Tiny Nair, Sushil Kumar Gupta, Ameya S Joshi, Show 8 more authorsPrakash Hazra

PRS Hospital; Manipal Hospital

AHA Scientific Sessions 2025 Abstract, 3 Nov 2025

Presented at AHA Scientific Sessions 2025, abstract 4371800

doi.org/10.1161/circ.152.suppl_3.4371800

Related